HB Fuller Company formulates, manufactures and markets adhesives, sealants, coatings, polymers, tapes, encapsulants, additives and other specialty chemicals worldwide. The company is headquartered in Saint Paul, Minnesota.
315 articles
H.B. Fuller rejected an unsolicited bid from Ancora Holdings and initiated a market check, while analysts suggest the stock is 27% undervalued due to ongoing margin optimization initiatives.
Activist investor Ancora Holdings demands a strategic review or sale from H.B. Fuller after rejecting a $1.2 billion–$1.4 billion offer for its Building Adhesive Solutions segment, citing poor governa
Ancora Holdings urged H.B. Fuller's Board to conduct a strategic review after rejecting its all-cash offer for the Building Adhesive Solutions segment. Citing high leverage, Ancora suggested a potenti
Ancora Holdings urges H.B. Fuller to pursue a full sale after rejecting a $1.2–1.4 billion offer for its adhesive segment, citing poor stock performance and debt.
HB Fuller Sr. VP Heather Campe filed a Form 4 on October 23rd, as reported by Investing.com.
H.B. Fuller successfully issued $850 million in senior notes due in 2034, with partial redemption tied to the Advanced Medical Solutions acquisition. The company is also reviewing potential divestitur
HB Fuller Company disclosed a Form 4 filing for Executive VP and CFO John J. Corkrean on October 23, with no further transaction details provided in the excerpt.
H.B. Fuller's CFO John J. Corkrean received 254.05 phantom units, bringing his total holdings to 36,659.66 units. These units convert to common stock upon specific termination events.
H.B. Fuller shares are analyzed as undervalued via DCF model despite a five-year decline, following a board decision to reject an offer for a key business segment.
TradingView provides financial estimates and analyst metrics for H. B. Fuller Company (NYSE: FUL), allowing comparison of actual results with valuation trends.
This article presents financial estimates and actuals for H.B. Fuller Company on the Dusseldorf Stock Exchange. It details valuation metrics and trends while noting the information is not investment a
H. B. Fuller shares rose 1.8% after Q3 fiscal 2026 earnings beat estimates with $1.52 EPS and $938.2M revenue. Driven by pricing and restructuring, the company outperformed the S&P 500 despite downwar
HB Fuller Company filed a Form 8K on October 22, 2026. The filing announcement provides limited details beyond the company name and submission date.
H.B. Fuller rejected a second unsolicited takeover bid from Ancora Holdings for its Building Adhesive Solutions business due to valuation disputes. The company subsequently announced a market review f
H.B. Fuller Company issued $850 million in senior unsecured notes to fund its acquisition of Advanced Medical Solutions Group PLC via subsidiary Bidco. This financing replaces the previously arranged
UBS reduced HB Fuller's price target to $55 from $69, reflecting a cautious outlook on the specialty adhesives and coatings firm's stock performance.
H.B. Fuller rejected activist investor Ancora's $1.2–1.4 billion offer for its Building Adhesive Solutions unit, deeming it modest. The company will conduct a market check of other segments by year-en
H.B. Fuller's board rejected Ancora's second unsolicited $1.2–1.4 billion offer for its Building Adhesive Solutions segment, deeming it insufficient. The company will conduct a market check on select
H.B. Fuller rejected Ancora Holdings Group's increased $1.2 billion to $1.4 billion offer for its Building Adhesive Solutions business, deeming it undervalued. Subsequently, the company initiated a ma
H.B. Fuller rejected Ancora's second offer for its Building Adhesive Solutions segment, citing undervaluation. Retaining BAS supports funding for medical asset integration and a strategic shift to hig
H.B. Fuller VP Muhammad Shahbaz Malik bought 479 shares after reporting adjusted EPS of $1.52, beating estimates despite revenue missing expectations. Analysts maintain a Moderate Buy rating with a pr
H.B. Fuller rejected Ancora's $1.2-1.4 billion offer for its building adhesives business, citing undervaluation. The company now plans to review and potentially separate noncore segments less integral
H.B. Fuller's board unanimously rejected Ancora's unsolicited $1.2–$1.4 billion takeover bid for its Building Adhesive Solutions division, deeming the offer undervalued.
H.B. Fuller rejected Ancora's $1.2–1.4 billion bid for its Building Adhesive Solutions business citing inadequate valuation. The company plans a market check for non-integral assets to fund debt reduc
H.B. Fuller's board unanimously rejected Ancora's unsolicited $1.2–$1.4 billion bid for its Building Adhesive Solutions business, citing undervaluation. The company will conduct a market check of sele
H.B. Fuller's board rejected Ancora's unsolicited $1.4 billion offer for its Building Adhesive Solutions segment, citing undervaluation. The company will conduct a market check on other segments to re
H.B. Fuller's board unanimously rejected Ancora's unsolicited $1.2 billion to $1.4 billion offer for its Building Adhesive Solutions segment, deeming it inadequate. The company will explore divesting
HB Fuller Company director R. Jeffrey Bailly filed a Form 4 regulatory disclosure for insider transactions ending September 30.
HB Fuller Company reported a Form 4 filing for Sr. VP Heather Campe regarding activity on October 9th. The filing details were not included in the Investing.com article published on October 17, 2026.
Deutsche Bank reduced its price target for H.B. Fuller to $62.00 from $72.00 while maintaining a Buy rating. The company's stock trades at EUR 45.80 ahead of its next earnings report on January 13, 20
ChemBrief